miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer

被引:50
|
作者
Fan, Yang [1 ]
Ma, Xin [1 ]
Li, Hongzhao [1 ]
Gao, Yu [1 ]
Huang, Qingbo [1 ]
Zhang, Yu [1 ]
Bao, Xu [2 ]
Du, Qingshan [1 ]
Luo, Guoxiong [1 ]
Liu, Kan [1 ]
Meng, Qingyu [1 ]
Zhao, Chaofei [1 ]
Zhang, Xu [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, PLA Med Sch, Dept Urol, State Key Lab Kidney Dis, Beijing, Peoples R China
[2] Nankai Univ, Med Sch, Tianjin, Peoples R China
基金
中国国家自然科学基金; 国家高技术研究发展计划(863计划);
关键词
clear cell renal cell carcinoma; microRNA; Dicer; prognosis; metastasis; migration; invasion; epithelial-mesenchymal transition; NATURAL-HISTORY; REPRESSORS ZEB1; IN-VIVO; EXPRESSION; CANCER; MICRORNAS; GENE; PHENOTYPE; PROGNOSIS; MIGRATION;
D O I
10.1002/ijc.31050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although overall downregulation of microRNAs (miRNAs) is a general feature of clear-cell renal cell carcinoma (ccRCC), several miRNAs are consistently upregulated, among which miR-122 was markedly increased in ccRCC tissues. Our study aims to determine the functional importance and underlying mechanism of miR-122 in ccRCC metastasis. Here, we demonstrate that the expression of miR-122 increased in ccRCC tissues, and higher miR-122 expression was found in ccRCC tissues with metastatic disease than in those without metastasis. The increased miR-122 levels were associated with poor metastasis-free survival in ccRCC patients with localized disease. Dicer was validated as a direct functional target of miR-122. Overexpression of miR-122 promoted migration and invasion of ccRCC cells in vitro and metastatic behavior of ccRCC cells in vivo. Inhibition of miR-122 attenuated this metastatic phenotype in vitro. Importantly, miR-122 exerted its pro-metastatic properties in ccRCC cells by downregulating Dicer and its downstream effector, the miR-200 family, thereby inducing epithelial-mesenchymal transition (EMT). Our results suggest an important role of the miR-122/Dicer/miR-200s/EMT pathway in ccRCC metastasis. Furthermore, miR-122 may serve as a biomarker for discriminating ccRCC with metastatic potential.
引用
收藏
页码:547 / 560
页数:14
相关论文
共 50 条
  • [31] PROSTATIC CLEAR-CELL LIKE LESIONS. THE RENAL-TYPE CLEAR-CELL CARCINOMA
    Olivieri, Valerio
    Orlassino, Renzo
    Pezzuto, Valter
    Bellei, Luca
    Massarelli, Massimo
    Ruggiero, Gabriele
    Corongiu, Emanuele
    Forte, Flavio
    Griffa, Daniele
    ANTICANCER RESEARCH, 2021, 41 (10) : 5292 - 5293
  • [33] Integrated molecular analysis of clear-cell renal cell carcinoma
    Yusuke Sato
    Tetsuichi Yoshizato
    Yuichi Shiraishi
    Shigekatsu Maekawa
    Yusuke Okuno
    Takumi Kamura
    Teppei Shimamura
    Aiko Sato-Otsubo
    Genta Nagae
    Hiromichi Suzuki
    Yasunobu Nagata
    Kenichi Yoshida
    Ayana Kon
    Yutaka Suzuki
    Kenichi Chiba
    Hiroko Tanaka
    Atsushi Niida
    Akihiro Fujimoto
    Tatsuhiko Tsunoda
    Teppei Morikawa
    Daichi Maeda
    Haruki Kume
    Sumio Sugano
    Masashi Fukayama
    Hiroyuki Aburatani
    Masashi Sanada
    Satoru Miyano
    Yukio Homma
    Seishi Ogawa
    Nature Genetics, 2013, 45 : 860 - 867
  • [34] Re: Sorafenib in advanced clear-cell renal cell carcinoma
    Karakiewicz, Pierre I.
    Hutterer, Georg
    EUROPEAN UROLOGY, 2007, 52 (01) : 279 - 280
  • [35] Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
    Vuong, Lynda
    Kotecha, Ritesh R.
    Voss, Martin H.
    Hakimi, A. Ari
    CANCER DISCOVERY, 2019, 9 (10) : 1349 - 1357
  • [36] Obesity, Cholesterol, and Clear-Cell Renal Cell Carcinoma (RCC)
    Drabkin, Harry A.
    Gemmill, Robert M.
    ADVANCES IN CANCER RESEARCH, VOL 107, 2010, 107 : 39 - 56
  • [37] miR-27a promotes cell proliferation and metastasis in renal cell carcinoma
    Peng, Hongjun
    Wang, Xianjun
    Zhang, Pei
    Sun, Tao
    Ren, Xianguo
    Xia, Zhengkun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (02): : 2259 - 2266
  • [38] Integrated molecular analysis of clear-cell renal cell carcinoma
    Sato, Yusuke
    Yoshizato, Tetsuichi
    Shiraishi, Yuichi
    Maekawa, Shigekatsu
    Okuno, Yusuke
    Kamura, Takumi
    Shimamura, Teppei
    Sato-Otsubo, Aiko
    Nagae, Genta
    Suzuki, Hiromichi
    Nagata, Yasunobu
    Yoshida, Kenichi
    Kon, Ayana
    Suzuki, Yutaka
    Chiba, Kenichi
    Tanaka, Hiroko
    Niida, Atsushi
    Fujimoto, Akihiro
    Tsunoda, Tatsuhiko
    Morikawa, Teppei
    Maeda, Daichi
    Kume, Haruki
    Sugano, Sumio
    Fukayama, Masashi
    Aburatani, Hiroyuki
    Sanada, Masashi
    Miyano, Satoru
    Homma, Yukio
    Ogawa, Seishi
    NATURE GENETICS, 2013, 45 (08) : 860 - U191
  • [39] Dystroglycan expression in clear-cell type renal cell carcinoma
    Camerini, A.
    De Luca, F.
    Genovese, G.
    De Paola, B.
    Valsuani, C.
    Tartarelli, G.
    Donati, S.
    Rettino, A.
    Cittadini, A.
    Sgambato, A.
    Gentili, C.
    Amoroso, D.
    ANNALS OF ONCOLOGY, 2006, 17 : XI34 - XI35
  • [40] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 125 - 134